{"entity":{"id":"nct02912949","kind":"trial","name":"A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)","aka":[],"tldr":"A phase 2 trial of Zenocutuzumab in non-small-cell lung cancer and pancreatic ductal adenocarcinoma, run by Partner Therapeutics, Inc., active and no longer recruiting.","summary":"A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) is a phase 2 interventional study registered as NCT02912949 by Partner Therapeutics, Inc., with 250 participants enrolled, started 2015-01 and due to reach its primary completion in 2026-12-31. Interventions recorded: zenocutuzumab (MCLA-128).","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT02912949","url":"https://clinicaltrials.gov/study/NCT02912949"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":["zenocutuzumab"],"companies":["partner-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT02912949","phase":"2","setting":"A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy)","sponsor":"Partner Therapeutics, Inc.","enrolled":250,"outcomes":[]},"route":"/trials/nct02912949/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"drug":[{"id":"zenocutuzumab","kind":"drug","name":"Zenocutuzumab","route":"/drugs/zenocutuzumab/"}],"company":[{"id":"partner-therapeutics","kind":"company","name":"Partner Therapeutics","route":"/companies/partner-therapeutics/"}]}}